Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 12 of 12 entries
View as:

Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT03120949 Org: User:
Start: 07/04/17 End: 09/01/21 Due: 09/01/22

Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine

Phase: N/A Priority: Normal
NCT ID: NCT05092776 Org: User:
Start: 04/29/21 End: 10/30/25 Due: 10/30/26

Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases

Phase: N/A Priority: Normal
NCT ID: NCT06440746 Org: User:
Start: 08/23/23 End: 12/25/28 Due: 12/25/29

Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis

Phase: N/A Priority: Normal
NCT ID: NCT05673902 Org: User:
Start: 12/11/20 End: 01/31/26 Due: 01/31/27

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

Phase: N/A Priority: Normal
NCT ID: NCT02760407 Org: User:
Start: 06/06/16 End: 11/05/19 Due: 11/05/20

Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

Phase: N/A Priority: Normal
NCT ID: NCT05190991 Org: User:
Start: 10/05/21 End: 01/31/29 Due: 01/31/30

Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)

Phase: N/A Priority: Normal
NCT ID: NCT04380519 Org: User:
Start: 04/23/20 End: 07/24/20 Due: 07/24/21

Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4

Phase: N/A Priority: Normal
NCT ID: NCT04246762 Org: User:
Start: 11/16/21 End: 10/26/22 Due: 10/26/23

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

Phase: N/A Priority: Normal
NCT ID: NCT02760368 Org: User:
Start: 05/19/16 End: 10/31/18 Due: 10/31/19

Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis

Phase: N/A Priority: Normal
NCT ID: NCT04692766 Org: User:
Start: 02/12/20 End: 03/22/22 Due: 03/22/23

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

Phase: N/A Priority: Normal
NCT ID: NCT02760433 Org: User:
Start: 01/25/17 End: 10/01/19 Due: 10/01/20

Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

Phase: N/A Priority: Normal
NCT ID: NCT05432960 Org: User:
Start: 12/31/23 End: 08/31/25 Due: 08/31/26